Safety, effectiveness and immunogenicity of heterologous mRNA-1273 boost after prime with Ad26.COV2.S among healthcare workers in South Africa: The single-arm, open-label, phase 3 SHERPA study
Authors: Garrett Nigel , Reddy Tarylee , Yende-Zuma Nonhlanhla , Takalani Azwidhwi , Woeber Kubashni , Bodenstein Annie , Jonas Phumeza , Engelbrecht Imke , Jassat Waasila , Moultrie Harry , Bradshaw Debbie , Seocharan Ishen , Odhiambo Jackline , Khuto Kentse , Richardson Simone I. , Omondi Millicent A. , Nesamari Rofhiwa , Keeton Roanne S. , Riou Catherine , Moyo-Gwete Thandeka , Innes Craig , Zwane Zwelethu , Mngadi Kathy , Brumskine William , Naicker Nivashnee , Potloane Disebo , Badal-Faesen Sharlaa , Innes Steve , Barnabas Shaun , Lombaard Johan , Gill Katherine , Nchabeleng Maphoshane , Snyman Elizma , Petrick Friedrich , Spooner Elizabeth , Naidoo Logashvari , Kalonji Dishiki , Naicker Vimla , Singh Nishanta , Maboa Rebone , Mda Pamela , Malan Daniel , Nana Anusha , Malahleha Mookho , Kotze Philip , Allagappen Jon J. , Diacon Andreas H. , Kruger Gertruida M. , Patel Faeezah , Moore Penny L. , Burgers Wendy A. , Anteyi Kate , Leav Brett , Bekker Linda-Gail , Gray Glenda E. , Goga Ameena ,   the SHERPA study team
Published: December 2024

Limited studies have been conducted on the safety and effectiveness of heterologous COVID-19 vaccine boosting in lower income settings, especially those with high-HIV prevalence., The Sisonke Heterologous mRNA-1273 boost after prime with Ad26.COV2.S (SHERPA) trial evaluated a mRNA-1273 boost after Ad26.COV2.S priming in South Africa. SHERPA was a single-arm, open-label, phase 3 study nested in the Sisonke implementation trial of 500000 healthcare workers (HCWs). Sisonke participants were offered mRNA-1273 boosters between May and November 2022, when Omicron sub-lineages were circulating. Adverse events (AE) were self-reported, and co-primary endpoints (SARS-CoV-2 infections and COVID-19 hospitalizations or deaths) were collected through national databases. We used Cox regression models with booster status as a time-varying covariate to determine the relative vaccine effectiveness (rVE) of the mRNA-1273 booster among SHERPA versus unboosted Sisonke participants. Of 11248 SHERPA participants in the rVE analysis cohort (79.3% female, median age 41), 45.4% had received one and 54.6% two Ad26.COV2.S doses. Self-reported comorbidities included HIV (18.7%), hypertension (12.9%) and diabetes (4.6%). In multivariable analysis including 413161 unboosted Sisonke participants, rVE of the booster was 59% (95%CI 29–76%) against SARS-CoV-2 infection: 77% (95%CI 9–94%) in the one-Ad26.COV2.S dose group and 52% (95%CI 13–73%) in the two-dose group. Severe COVID-19 was identified in 148 unboosted Sisonke participants, and only one SHERPA participant with severe HIV-related immunosuppression. Of 11798 participants in the safety analysis, 228 (1.9%) participants reported 575 reactogenicity events within 7 days of the booster (most commonly injection site pain, malaise, myalgia, swelling, induration and fever). More reactogenicity events were reported among those with prior SARS-CoV-2 infections (adjusted odds ratio [aOR] 2.03, 95%CI 1.59–2.59) and less among people living with HIV (PLWH) (aOR 0.49, 95%CI 0.34–0.69). There were 115 unsolicited adverse events (AEs) within 28 days of vaccination. No related serious AEs were reported. In an immunogenicity sub-study, mRNA-1273 increased binding and neutralizing antibody titres and spike-specific T-cell responses 4 weeks after boosting regardless of the number of prior Ad26.COV2.S doses, or HIV status, and generated Omicron spike-specific cross-reactive responses. mRNA-1273 boosters after one or two Ad26.COV2.S doses were well-tolerated, safe and effective against Omicron SARS-CoV-2 infections among HCWs and PLWH.

Trial registration: The SHERPA study is registered in the Pan African Clinical Trials Registry (PACTR): PACTR202310615330649 and the South African National Clinical Trial Registry (SANCTR): DOH-27-052022-5778.